1206800-24-9

Basic information

• Product Name: 6-broMo-5-(2-fluoro-4-nitrophenoxy)-1-Methyl-1H-indazole
• Synonyms: 6-broMo-5-(2-fluoro-4-nitrophenoxy)-1-Methyl-1H-indazole;1H-Indazole, 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1-methyl-
• CAS NO: 1206800-24-9
• Molecular Formula: C₁₄H₉BrFN₃O₃
• Molecular Weight: 366.1419632
• Mol File: 1206800-24-9.mol

Chemical Properties

• Boiling Point: 435.0±45.0 °C(Predicted)
• Appearance: /
• Density: 1.70±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -0.31±0.30(Predicted)
• CAS DataBase Reference: 6-broMo-5-(2-fluoro-4-nitrophenoxy)-1-Methyl-1H-indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 6-broMo-5-(2-fluoro-4-nitrophenoxy)-1-Methyl-1H-indazole(1206800-24-9)
• EPA Substance Registry System: 6-broMo-5-(2-fluoro-4-nitrophenoxy)-1-Methyl-1H-indazole(1206800-24-9)

Safety Data

• Hazardous Substances Data: 1206800-24-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
6-bromo-5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazole is used as a reactant in the synthesis of more complex molecules, particularly for the development of pharmaceuticals and bioactive compounds. Its diverse functional groups and reactive moieties make it a promising candidate for creating new drug molecules with potential therapeutic applications.
Used in Bioactive Compound Production:
In the field of biochemistry, 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazole is used as a building block for the production of bioactive compounds. Its structural complexity and the presence of multiple functional groups allow for the creation of molecules with specific biological activities, which could be utilized in research and development of new therapeutic agents.
Note: The specific applications and uses mentioned above are hypothetical and based on the potential reactivity of the compound's functional groups. More detailed information and research would be required to confirm the exact applications and benefits of 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazole in these fields.

InChI:InChI=1S/C14H9BrFN3O3/c1-18-12-6-10(15)14(4-8(12)7-17-18)22-13-3-2-9(19(20)21)5-11(13)16/h2-7H,1H3

Upstream product

• 1206800-19-2 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1H-indazole 
• 74-88-4 methyl iodide 
• 1577179-97-5 6-bromo-5-methoxy-1-methyl-1H-indazole 
• 369-34-6 3,4-difluoronitrobenzene 
• 1403767-19-0 6-bromo-1-methyl-1H-indazol-5-ol 
• 100-83-4 meta-hydroxybenzaldehyde 
• 3111-51-1 2,4-dibromo-5-hydroxybenzaldehyde 
• 1577180-04-1 C₉H₁₀Br₂N₂O 
• 1206800-17-0 6-bromo-5-methoxy-1H-indazole 
• 1206800-18-1 6-bromo-1H-indazol-5-ol 
• 1206800-25-0 2,4-dibromo-5-(2-fluoro-4-nitrophenoxy) benzaldehyde 
• 1206800-27-2 6-bromo-2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-5-ol 
• 1206800-28-3 6-bromo-5-(2-fluoro-4-nitrophenoxy)-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 

Downstream Products

• 1206800-75-0 N-(diphenylmethylene)-5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazol-6-amine 
• 1206800-43-2 5-(2-Fluoro-4-nitrophenoxy)-1-methyl-6-(1 H-pyrazol-4-yl)-1H-indazole 
• 1206800-42-1 tert-butyl 4-(5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate 
• 1206799-15-6 N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 
• 1206800-56-7 tert-butyl 4-(5-(4-amino-2-fluorophenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate 
• 1206801-36-6 tert-butyl 4-(5-(2-fluoro-4-(1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamido)phenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate 
• 1206800-67-0 3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)aniline 
• 1577180-07-4 N-(4-((6-bromo-1-methyl-1H-indazol-5-yl)oxy)-3-fluorophenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 

Relevant articles and documents

An Alternative Indazole Synthesis for Merestinib

A new synthesis of a key indazole-containing building block for the MET kinase inhibitor merestinib was designed and demonstrated. Crucial to the successful construction of the challenging indazole is an SNAr reaction, which forges the heterocy

TRK INHIBITOR AS ANTI-CANCER DRUG

The present disclosure relates to a group of tropomyosin receptor kinase inhibitors comprising an amido-phenoxy-indazole structure fragment. These compounds show potent inhibitory effects on various oncogenic kinases, especially TRK, and thus can be used

Route design and development of a MET kinase inhibitor: A copper-catalyzed preparation of an N 1 - Methylindazole

The synthesis of a MET kinase inhibitor in an overall yield of 22% was achieved over eight steps starting with 3-hydroxybenzaldehyde, an improvement from the initial 12-step process with a 5.4% yield. Highlights of the process chemistry design and development are a Cu-catalyzed cyclization to form an important N1-methylindazole ring, a selective nitro reduction in the presence of an aryl bromide, a late-stage Suzuki cross-coupling, and a base-promoted Boc deprotection to form the desired drug candidate.

AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET

The present invention provides amidophenoxyindazole compounds useful in the treatment of cancer.